

Diamines and Chemicals Limited

Disclosures with respect to Compliance to section 62 of the Companies Act, 2013 read with Rule 12 of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of the SEBI (Share Based Employee Benefits And Sweat Equity) Regulations, 2021 (ESOP Disclosures) as on March 31, 2021

During the year there was no material change in the ESOS schemes of the Company. The ESOS Schemes are in Compliance with the regulations. The DACL – Employee Stock Option Plan – 2021 (ESOP Scheme) was approved by the Shareholder under SEBI (Share Based Employee Benefits) Regulations, 2014 by Special Resolution on July 20, 2021. Further, ESOP Scheme is getting amended by making regulatory amendments only under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. There was no grant of shares during the year ended March 32, 2022.

A. Relevant disclosures in terms of the accounting standards prescribed by the Central Government in terms of section 133 of the Companies Act, 2013 (18 of 2013) including the 'Guidance note on accounting for employee share-based payments' issued in that regard from time to time.

Members may refer to the audited financial statement prepared as per Ind AS for the year 2021-22.

B. Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by Central Government or any other relevant accounting standards as issued from time to time.

C. Details related to ESOS

(i) A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS, including -

	Particulars	DACL- Employee Stock Option Scheme -2021
(a)	Date of shareholders' approval	July 20, 2021
(b)	Total number of options approved under ESOS	2,00,000
(c)	Vesting requirements	Vesting of the Stock Options may commence after the expiry of a minimum period of 1 (one) year from the date on which the options were granted, and may extend up to such time as may be decided at the discretion of the Committee from the date of grant provided that the vesting period shall not exceed 5 (five) years. The vesting may occur in tranches, and may be subject to such terms and conditions of vesting, as may be stipulated by the Committee, in its sole and exclusive discretion.

(d)	Exercise price or pricing formula	The Exercise Price shall be as may be decided by the Committee as is allowed under the SBEB Regulations which in any case will not be lower than the face value of the equity shares of the Company on the date of such grant. Further the Exercise Price can be different for different set of employees for options granted on same / different dates.
(e)	Maximum term of options granted	The Exercise period shall not be more than 5 years from the date of respective vesting of Options. The options granted may be exercised by the Grantee at one time or at various points of time within the exercise period as determined by the Committee from time to time.
(f)	Source of shares (primary, secondary or combination)	Primary
(g)	Variation in terms of options	Only regulatory amendments

- (ii) Method used to account for ESOS - Intrinsic or fair value. – Fair Value
- (iii) Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.
- (iv) Option movement during the year (For each ESOS):

Particulars	Details
Number of options outstanding at the beginning of the period	2,00,000
Number of options granted during the year	NIL
Number of options forfeited / lapsed during the year	NA
Number of options vested during the year	NIL
Number of options exercised during the year	NIL
Number of shares arising as a result of exercise of options	NIL
Money realized by exercise of options (INR), if scheme is implemented directly by the company	NIL
Loan repaid by the Trust during the year from exercise price received	NA
Number of options outstanding at the end of the year	2,00,000
Number of options exercisable at the end of the year	2,00,000

- (v) Weighted-average exercise prices and weighted-average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock. Not Applicable
- (vi) Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to -
- (a) senior managerial personnel as defined under Regulation 16(d) of the Securities and

Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; - NIL

- (b) any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year; and - NIL
 - (c) identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant. – Not Applicable
- (vii) A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:
- (a) the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model;
 - (b) the method used and the assumptions made to incorporate the effects of expected early exercise;
 - (c) how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and
 - (d) whether and how any other features of the options granted were incorporated into the measurement of fair value, such as a market condition.

Disclosures in respect of grants made in three years prior to IPO under each ESOS

Until all options granted in the three years prior to the IPO have been exercised or have lapsed, disclosures of the information specified above in respect of such options shall also be made. – Not Applicable